Stockreport

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

MELINTA THERAPEUTICS INC  (MLNT) 
Last melinta therapeutics inc earnings: 11/12 04:39 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.melinta.com/investor-relations
PDF NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing nov [Read more]